Future directions in antithrombotic therapy: Emphasis on venous thromboembolism

Journal of the American College of Surgeons

Volumn 192, Issue 5, 2001, Pages 641-651

  Axelrod, David A ^a,b,c   Wakefield, Thomas W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANCROD; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; HIRUDIN; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; RIDOGREL; ROXIFIBAN; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; XEMILOFIBAN;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; DRUG MECHANISM; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR ENDOTHELIUM; VEIN CATHETERIZATION; VEIN THROMBOSIS;

EID: 0035023904     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(01)00826-2     Document Type: Article

References (61)

1. Evolution of therapies in deep vein thrombosis management
2. Thrombosis and anticoagulation
3. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled study
4. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis
5. Prevention of postoperative pulmonary embolism by low doses of heparin
6. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
7. Low-molecular-weight heparins compared with unfractionated, heparin for the treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
8. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage
9. Heparin-associated thrombocytopenia: A critical review and a pooled analysis
10. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis
11. Contemporary use of and future roles for heparin in antithrombotic therapy
12. A comparative, double-blind, randomized trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism
13. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis
14. Deep-vein thrombosis
15. New heparin complexes active by intestinal absorption, I: Multiple ion pairs with basic organic compounds
16. Orally administered heparin for preventing deep venous thrombosis
17. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis
18. Oral delivery of anticoagulent doses of heparin: A randomized, double-blind, controlled study in humans
19. Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat
20. Thrombolytic therapy for acute deep vein thrombosis
21. Iliofemoral deep venous thrombosis: Aggressive therapy with catheter-directed thrombolysis
22. The long term clinical course of acute deep venous thrombosis
23. Catheter-directed thrombolysis for lower extremity deep venous thrombosis. Report of a national multicenter registry
24. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children
25. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life
26. A comparison of reteplase with alteplase for acute miocardial infarction
27. Randomized comparison of coronary thrombolysis achieved with double bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
28. Reteplase in the treatment of peripheral arterial and venous occlusions: A pilot study
29. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
30. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
31. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multicenter prospective dose-ranging randomized trial
32. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: A randomized trial
33. Clinical experience of Argatroban for anticoagulation in cardiovascular surgery
34. Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons
35. Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin(rHV2-Lys 47) after repeated intravenous administration in dogs
36. Fibrinogen depleting agents for acute ischaemic stroke (Cochrane Review)
37. Ancrod as prophylaxis or treatment for thromboembolism in patients with multiple trauma
38. Ancrod versus heparin for anticoagulation during vascular surgical procedures
39. Ancrod. The use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: Nursing management
40. Intravenous Ancrod for treatment of acute ischemic stroke
41. Ancrod-is snake venom an antidote for stroke?
42. Overview of prevention of venous thromboembolism
43. Adjuvant medical therapy in peripheral bypass surgery
44. Collaborative overview of randomized trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
45. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
46. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials
47. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting
48. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel aspirin stent international cooperative study (CLASSICS)
49. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
50. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease
51. Synthetic inhibitors of platelet glycoprotein IIb/ Ilia in clinical development
52. Neutrophils and deep venous thrombosis
53. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
54. A recombinant soluble P-selectin glycoprotein ligand-1 chimera has a thrombolytic effect in a rat model of thrombosis
55. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulant therapy
56. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa
57. Peptide exosite inhibitors of factor Vita as anticoagulants
58. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C
59. Effect of activated human Protein C on experimental venous thrombosis induced by stasis with operative invasion in mice